More Phase III Exubera data

Partners Pfizer (PFE), Aventis (AVE) and Inhale (INHL) reported that in a Phase III trial of 309 patients with Type II diabetes who had failed to meet recommended blood glucose levels with combination oral therapy, their Exubera inhaled insulin alone or in combination with oral agents improved glycemic control compared to patients receiving oral agents alone. The Exubera patients also had bigger decreases in fasting plasma glucose concentrations and two-hour post-meal glucose levels compared to patients taking only oral agents.

Hypoglycemia and weight gain were higher in Exubera patients. Antibody serum binding was increased in Exubera patients, but the companies said there "did not appear to be any related clinical significance." Pulmonary function tests were similar between the groups. ...